<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Patient Prefer Adherence</journal-id><journal-id journal-id-type="iso-abbrev">Patient Prefer Adherence</journal-id><journal-id journal-id-type="publisher-id">Patient Preference and Adherence</journal-id><journal-title-group><journal-title>Patient preference and adherence</journal-title></journal-title-group><issn pub-type="epub">1177-889X</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29033550</article-id><article-id pub-id-type="pmc">5614776</article-id><article-id pub-id-type="doi">10.2147/PPA.S141267</article-id><article-id pub-id-type="publisher-id">ppa-11-1613</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Coach to cope: feasibility of a life coaching program for young adults with cystic fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Knudsen</surname><given-names>Karin B&#x000e6;k</given-names></name><xref ref-type="aff" rid="af1-ppa-11-1613">1</xref><xref ref-type="corresp" rid="c1-ppa-11-1613"/></contrib><contrib contrib-type="author"><name><surname>Pressler</surname><given-names>Tacjana</given-names></name><xref ref-type="aff" rid="af2-ppa-11-1613">2</xref></contrib><contrib contrib-type="author"><name><surname>Mortensen</surname><given-names>Laust Hvas</given-names></name><xref ref-type="aff" rid="af3-ppa-11-1613">3</xref></contrib><contrib contrib-type="author"><name><surname>Jarden</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="af3-ppa-11-1613">3</xref><xref ref-type="aff" rid="af4-ppa-11-1613">4</xref></contrib><contrib contrib-type="author"><name><surname>Boisen</surname><given-names>Kirsten Arntz</given-names></name><xref ref-type="aff" rid="af5-ppa-11-1613">5</xref></contrib><contrib contrib-type="author"><name><surname>Skov</surname><given-names>Marianne</given-names></name><xref ref-type="aff" rid="af2-ppa-11-1613">2</xref></contrib><contrib contrib-type="author"><name><surname>Quittner</surname><given-names>Alexandra L</given-names></name><xref ref-type="aff" rid="af6-ppa-11-1613">6</xref></contrib><contrib contrib-type="author"><name><surname>Katzenstein</surname><given-names>Terese Lea</given-names></name><xref ref-type="aff" rid="af1-ppa-11-1613">1</xref><xref ref-type="aff" rid="af7-ppa-11-1613">7</xref></contrib></contrib-group><aff id="af1-ppa-11-1613">
<label>1</label>Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark</aff><aff id="af2-ppa-11-1613">
<label>2</label>Cystic Fibrosis Center Copenhagen, Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark</aff><aff id="af3-ppa-11-1613">
<label>3</label>Department of Public Health, University of Copenhagen, Copenhagen, Denmark</aff><aff id="af4-ppa-11-1613">
<label>4</label>University Hospital Center for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark</aff><aff id="af5-ppa-11-1613">
<label>5</label>Center of Adolescent Medicine, Department of Pediatric and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark</aff><aff id="af6-ppa-11-1613">
<label>6</label>Miami Children&#x02019;s Research Institute, Miami, FL, USA</aff><aff id="af7-ppa-11-1613">
<label>7</label>Department of Clinical Medicine, Faculty of Health and Social Sciences, University of Copenhagen, Copenhagen, Denmark</aff><author-notes><corresp id="c1-ppa-11-1613">Correspondence: Karin B&#x000e6;k Knudsen, Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark, Tel +45 3545 3456, Fax +45 3545 2975, Email <email>karin.baek.knudsen.01@regionh.dk</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>21</day><month>9</month><year>2017</year></pub-date><volume>11</volume><fpage>1613</fpage><lpage>1623</lpage><permissions><copyright-statement>&#x000a9; 2017 Knudsen et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Over the last two decades, lifespan has increased significantly for people living with cystic fibrosis (CF). However, several studies have demonstrated that many young adults with CF report mental health problems and poor adherence to their prescribed treatments, challenging their long-term physical health. Treatment guidelines recommend interventions to improve adherence and self-management. The aim of this study was to test the feasibility of a life coaching intervention for young adults with CF.</p></sec><sec><title>Methods</title><p>A randomized, controlled feasibility study was conducted at the CF Center at Copenhagen University Hospital, Rigshospitalet. Participants were young adults with CF, aged 18&#x02013;30 years without severe intellectual impairments. Participants were randomized to either life coaching or standard care. The intervention consisted of up to 10 individual, face-to-face or telephone coaching sessions over a period of 1 year. Primary outcomes were recruitment success, acceptability, adherence to the intervention, and retention rates. Secondary outcome measures included health-related quality of life, adherence to treatment, self-efficacy, pulmonary function, body mass index, and blood glucose values.</p></sec><sec><title>Results</title><p>Among the 85 eligible patients approached, 40 (47%) were enrolled and randomized to the intervention or control group; two patients subsequently withdrew consent. Retention rates after 5 and 10 coaching sessions were 67% and 50%, respectively. Reasons for stopping the intervention included lack of time, poor health, perceiving coaching as not helpful, lack of motivation, and no need for further coaching. Coaching was primarily face-to-face (68%). No significant differences were found between the groups on any of the secondary outcomes.</p></sec><sec><title>Conclusion</title><p>Both telephone and face-to-face coaching were convenient for participants, with 50% receiving the maximum offered coaching sessions. However, the dropout rate early in the intervention was a concern. In future studies, eligible participants should be screened for their interest and perceived need for support and life coaching before enrollment.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>life coaching</kwd><kwd>adherence</kwd><kwd>depression</kwd><kwd>quality of life</kwd><kwd>chronic disease</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Cystic fibrosis (CF) is a genetic, life shortening, multiorgan disease which primarily affects the pulmonary and digestive systems.<xref rid="b1-ppa-11-1613" ref-type="bibr">1</xref> Pulmonary exacerbations are the primary cause of increased morbidity and earlier mortality.<xref rid="b2-ppa-11-1613" ref-type="bibr">2</xref> However, optimization of medical treatment has improved lifespan, which is now projected to be over 50 years if mortality continues to decrease at the rate observed between 2000 and 2010.<xref rid="b3-ppa-11-1613" ref-type="bibr">3</xref> The treatment regimen includes daily preventive home treatments and intensified inpatient or outpatient treatments during pulmonary exacerbations.<xref rid="b4-ppa-11-1613" ref-type="bibr">4</xref> Despite inevitable declines in health and the challenges of managing CF on a daily basis, the majority of young adults with CF are either employed or enrolled in a college or university. However, many young adults report elevated symptoms of depression and anxiety,<xref rid="b5-ppa-11-1613" ref-type="bibr">5</xref> poor adherence to prescribed treatments,<xref rid="b6-ppa-11-1613" ref-type="bibr">6</xref> and decrements in health-related quality of life (HRQoL).<xref rid="b7-ppa-11-1613" ref-type="bibr">7</xref></p><p>Achieving an acceptable balance between taking responsibility for CF care and living a &#x0201c;normal&#x0201d; life, both professionally and socially, is a major challenge. Multiple barriers to adherence to treatment have been identified (ie, time constraints, competing priorities, and accidental and purposeful forgetting).<xref rid="b8-ppa-11-1613" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-ppa-11-1613" ref-type="bibr">10</xref> Consensus reports have recommended the development and evaluation of interventions to improve mental health, coping skills, and daily management of the disease.<xref rid="b5-ppa-11-1613" ref-type="bibr">5</xref>,<xref rid="b11-ppa-11-1613" ref-type="bibr">11</xref></p><p>A systematic review of interventions aimed at improving adherence to prescribed CF medications found that even the most effective interventions did not lead to large improvements.<xref rid="b12-ppa-11-1613" ref-type="bibr">12</xref> Education and training in self-management (eg, life coaching) may be effective in facilitating patient adherence and management of daily stressors. Modest evidence suggests that self-management education has positive effects on these behavioral changes.<xref rid="b13-ppa-11-1613" ref-type="bibr">13</xref> Current evidence for the efficacy of psychological interventions for individuals with CF is limited. The most convincing results have been found for cognitive-behavioral interventions.<xref rid="b14-ppa-11-1613" ref-type="bibr">14</xref> Motivational interviewing (MI), a patient-centered form of counseling which helps patients resolve ambivalence in regard to behavior change, is primarily designed to increase motivation and commitment to change.<xref rid="b15-ppa-11-1613" ref-type="bibr">15</xref> MI is most often used in combination with other programs and moderately efficacious results have been reported.<xref rid="b16-ppa-11-1613" ref-type="bibr">16</xref> Coaching interventions overlap with the principles of MI, whereas the focus of MI is primarily on increasing motivation for specific behavior change, coaching is a whole-person model, which includes all life aspects.<xref rid="b17-ppa-11-1613" ref-type="bibr">17</xref> We hypothesized that a coaching intervention would empower young adults with CF to manage their treatment and daily functioning more effectively, thus improving health outcomes and HRQoL. Few studies have evaluated coaching interventions; thus, the primary aim of this study was to establish the feasibility of a coaching intervention for young adults with CF. Secondary aims included evaluating its effects on health outcomes and HRQoL.</p></sec><sec sec-type="methods"><title>Methods</title><sec sec-type="methods"><title>Design</title><p>This feasibility study was a prospective, two-arm, randomized controlled trial comparing a life coaching intervention to a control group receiving standard care at a Danish CF Center.</p></sec><sec sec-type="methods|subjects"><title>Patients and procedures</title><p>Study participants were recruited at the outpatient CF clinic at the Department of Infectious Diseases at Copenhagen University Hospital, Rigshospitalet, one of two hospitals in Denmark at which CF treatment is centralized. The department treat&#x0015d;200 adults with CF. All patients are scheduled to visit the outpatient clinic on a monthly basis. At these visits, the treating physicians (TP and TLK) or investigator and study coach (KBK) informed patients about the study. Patients who did not attend the sessions on a monthly basis received information about the study by letter; if there was no response, phone calls were made to determine the level of interest.</p><p>Eligible patients were between 18 and 30 years with a confirmed CF diagnosis by clinical findings, identification of two disease causing CFTR mutations, and a positive sweat chloride test. Exclusion criteria included severe intellectual impairment or insufficient mastery of the Danish language, determined by the inability to complete the questionnaires independently. After written informed consent, baseline data were collected and participants were randomized 1:1 in computer-generated blocks of four, to obtain equal numbers in both arms. We aimed to recruit 40 participants.</p><p>This study was conducted in accordance with the Declaration of Helsinki 2004 and all participants signed consent forms. This study was reviewed by the regional ethics committee of the Capital Region of Denmark and deemed exempt from a formal evaluation (H-2-2013-FSP01); it was registered at the Danish Data Protection Agency (j nr 30-0918) and at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (ID NCT02110914).</p></sec><sec><title>Coaching intervention</title><p>All participants were given standard-of-care treatment and were randomized to either life coaching or the control condition. All coaching sessions were delivered by one nurse (KBK) experienced with CF, certified by an Accredited Coaching Training Program, which included 125 student contact hours, 10 hours of mentor coaching, and a performance evaluation.<xref rid="b18-ppa-11-1613" ref-type="bibr">18</xref> Participants allocated to coaching (coachees) were offered up to 10 individual coaching sessions. The first and the last coaching sessions were intended to be face-to-face and last up to 90 minutes. Other coaching sessions could be carried out either face-to-face or by telephone, according to participants&#x02019; preference, and lasted up to 60 minutes. Coaching sessions were scheduled every 1&#x02013;2 weeks early in the program and every 2&#x02013;4 weeks later on. The entire coaching intervention was planned to last 6&#x02013;9 months. Coaching took place either in a quiet room at the hospital outside the Department of Infectious Diseases or at a location close to the hospital.</p><p>The intervention was based on a life coaching model that was carried out in successive steps.<xref rid="b19-ppa-11-1613" ref-type="bibr">19</xref>,<xref rid="b20-ppa-11-1613" ref-type="bibr">20</xref>
<list list-type="order"><list-item><p>The coach started by building a rapport and encouraging the coachee to tell his/her story.</p></list-item><list-item><p>The most important concern for the coachee was identified.</p></list-item><list-item><p>Goals were set by the coachee.</p></list-item><list-item><p>Barriers for achieving these goals were identified.</p></list-item><list-item><p>Collaborative action, consistent with the coachee&#x02019;s values, was planned.</p></list-item><list-item><p>Progress was evaluated and new action plans and goals were negotiated.</p></list-item></list></p><p>The coaching intervention included the following elements: client-centeredness, empathy and collaboration, focus on preferences, reflective dialogue, use of positive language, and promotion of capacity and self-determination.<xref rid="b21-ppa-11-1613" ref-type="bibr">21</xref> Sessions included different tools; for example, &#x0201c;the wheel of life&#x0201d;<xref rid="b19-ppa-11-1613" ref-type="bibr">19</xref> on which coachees could rate their level of satisfaction in different life areas. &#x0201c;Time management&#x0201d;<xref rid="b22-ppa-11-1613" ref-type="bibr">22</xref> was used to help participants structure and prioritize their time. Describing an ideal day or a dream for the future was integrated into the session to identify the participants&#x02019; values and short- and long-term goals. Finally, participants who reported symptoms of stress were guided to improve sleeping habits, engage in moderate physical exercise, and use mindfulness strategies, according to recommendations from The Danish Health Authority.<xref rid="b23-ppa-11-1613" ref-type="bibr">23</xref></p></sec><sec><title>Measurements</title><sec sec-type="methods"><title>Primary study outcome</title><p>The primary outcome for this study was an evaluation of its feasibility. Feasibility measures were described by Bowen et al<xref rid="b24-ppa-11-1613" ref-type="bibr">24</xref> and included the following.
<list list-type="order"><list-item><p>Acceptability: How individuals responded to the intervention was assessed by analyzing dropout rates and reasons for dropout.</p></list-item><list-item><p>Demand: We assessed interest in this type of intervention by comparing the recruitment rate with the number of eligible participants.</p></list-item><list-item><p>Practicality and implementation: Barriers and facilitators for implementation of the coaching intervention were evaluated by documenting the following variables in a logbook for each participant: total number of sessions, their frequency, duration of the coaching sessions, and mode of delivery (telephone or face-to-face). The content of the coaching sessions was confidential, but topics, process, and the use of different tools were also noted in the logbook.</p></list-item><list-item><p>Efficacy assessment: Intended effects of the coaching intervention were measured by patient-reported outcomes (PROs) and clinical parameters.</p></list-item></list></p></sec><sec><title>Demographic and disease information</title><p>Baseline demographic data were collected through questionnaires. Disease information was obtained through medical chart review and included CF mutations, body mass index (BMI), lung function, (forced expiratory volume in 1 second [FEV<sub>1</sub>]), glycated hemoglobin (HbA1C), chronic lung infection, and CF-related diabetes.</p></sec><sec sec-type="methods"><title>Secondary study outcomes</title><p>The clinical parameters BMI, FEV<sub>1</sub>, and HbA1C, and PRO measures of adherence, depression, HRQoL, and self-efficacy were obtained as secondary outcome measures. The data collection took place at four time points (baseline), midway (after 5 months), post-intervention (after 11 months), and at follow-up (1 year post-intervention). Participants in the intervention group, who stopped after a few coaching sessions, completed the assessment at the same time points as the control group. Adherence was assessed by a validated, 8-item questionnaire, the Morisky Medication Adherence Scale-8 item (MMAS-8).<xref rid="b25-ppa-11-1613" ref-type="bibr">25</xref>&#x02013;<xref rid="b27-ppa-11-1613" ref-type="bibr">27</xref> Adherence to the following treatments was assessed: dornase alfa inhalation, pancreatic enzymes, supplement vitamins (ADEK), inhaled antibiotic therapy, and positive expiratory pressure (PEP) therapy. To assess psychological well-being, two validated depression screening instruments were used: the Major Depression Inventory<xref rid="b28-ppa-11-1613" ref-type="bibr">28</xref> and Center for Epidemiologic Studies-Depression Scale.<xref rid="b29-ppa-11-1613" ref-type="bibr">29</xref> To assess HRQoL, the Cystic Fibrosis Questionnaire-Revised-Teen/Adult version (CFQ-R)<xref rid="b30-ppa-11-1613" ref-type="bibr">30</xref> was completed; it is a validated, disease-specific HRQoL instrument for CF. The CFQ-R assesses demographic information (eg, age, education) and symptoms and functioning across 12 domains: Physical Functioning, Vitality, Emotional Functioning, Eating Disturbances, Treatment Burden, Health Perceptions, Social Functioning, Body Image, Role Functioning, Weight, Respiratory Symptoms, and Digestive Symptoms. Scores are standardized and range from 0 to 100, with higher scores indicating better HRQoL. The Generalized Self-Efficacy scale,<xref rid="b31-ppa-11-1613" ref-type="bibr">31</xref> a 10-item validated scale, measured self-efficacy beliefs.</p></sec></sec><sec><title>Statistical analyses</title><p>Baseline comparisons of demographic and disease characteristics were performed by using an independent sample <italic>t</italic>-test for continuous variables and Fishers exact test for categorical variables. Descriptive statistics (means and standard deviations [SDs]) were used to describe the sample. Data were analyzed using a two-way repeated measures analysis of variance (ANOVA) with a within-subject factor of time (baseline, midway, post-intervention, and follow-up) and a between-subject factor of group (coaching/control). Missing data were not imputed, and since ANOVA uses listwise deletion for missing data, the sample was reduced to 18 participants (coaching group: n=7/control group: n=11). Mauchly&#x02019;s test indicated that the assumption of sphericity had been violated; therefore, degrees of freedom were corrected using Greenhouse&#x02013;Geisser estimates of sphericity. A <italic>P</italic>-value &#x0003c;0.05 was considered statistically significant. Effect size calculations were computed using partial eta squared (partial &#x003b7;<sup>2</sup>), whereby an effect size of 0.03 is considered small, 0.13 medium, and 0.26 large effects. This feasibility study was not powered to evaluate the efficacy of the intervention. All results should therefore be considered preliminary. Statistical analyses were performed using SPSS version 22 (SPSS Inc, IBM Corporation, Armonk, NY, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="intro"><title>Participant characteristics</title><p>In total, 92 patients aged 18&#x02013;30 years, with a confirmed diagnosis of CF, were eligible. Three patients were abroad and four patients were excluded due to cognitive impairment. Thus, 85 eligible adults were invited to participate. We continued to enroll individuals until we reached our intended number of 40 participants. This represented 47% of eligible participants at this adult CF Center. Fifteen young adults declined participation (18%) and 30 (35%) never responded. After randomization, two participants withdrew consent; thus, the final sample consisted of 38 participants (intervention, n=18 and control, n=20; <xref ref-type="fig" rid="f1-ppa-11-1613">Figure 1</xref>). Demographic and baseline clinical characteristics are shown in <xref ref-type="table" rid="t1-ppa-11-1613">Table 1</xref>. Most participants were female (71%), were employed or studying (87%), and half of the participants (50%) had average FEV<sub>1</sub> values above 70% of predicted. The intervention and the control group were comparable, but there were more participants with CF-related diabetes in the intervention group (44%) versus the control group (20%) and clinical parameters like FEV<sub>1</sub>, BMI, and HbA1C were slightly, but not significantly, worse in the intervention group.</p></sec><sec><title>Feasibility</title><p>Feasibility of the study was evaluated using data on acceptability, practicality and implementation, and limited efficacy testing.<xref rid="b24-ppa-11-1613" ref-type="bibr">24</xref></p><sec><title>Acceptability</title><p>Acceptability was assessed using data on dropout rates and reasons for dropout. Retention rates after 5 and 10 coaching sessions were 67% and 50%, respectively. Reasons for stopping the intervention included lack of time (n=1), poor health (n=1), coaching not being helpful (n=2), lack of motivation (n=1), no need for further coaching (n=2), and unknown reasons (n=2). Those who stopped because of &#x0201c;no need for further coaching&#x0201d; were not considered dropouts, as they had achieved what they wanted from the coaching intervention in &#x0003c;10 sessions. Thus, the dropout rate overall was 39%.</p></sec><sec><title>Practicality and implementation</title><p>In total, 121 coaching sessions were performed. The majority of sessions were face-to-face sessions (n=82; 68%) and lasted on average 57 minutes (range 20&#x02013;110). Thirty-nine coaching sessions were carried out by telephone (32%) and lasted on average 28 minutes (range 5&#x02013;60). Telephone sessions were most often requested by participants who lived at a long distance from the hospital or who were feeling successful in implementing their action plans; they were primarily interested in having a call to evaluate their progress and, if necessary, adjust their plans. Telephone coaching was also used by participants to save time.</p><p>The number of same-day cancelations was 38 (31%); five (6 %) were no-shows. Planned telephone coaching calls were not answered 10 times (25%). Individuals who cancelled or were no-shows for in-person or telephone sessions were offered new appointments. Due to the number of cancellations, it was not possible to adhere to the original schedule of intervals between coaching sessions. The time frame for completion of the coaching program varied; however, those who participated in all 10 sessions completed in 8&#x02013;15 months. The topics discussed in these sessions also varied across participants. The most frequently chosen topics were 1) work/study&#x02013;life balance, 2) treatment adherence, 3) stress reduction, 4) time management, 5) establishing priorities, and 6) improving eating or exercise habits. Many participants had difficulty in choosing a topic and setting goals at the first coaching session, but as evidenced by their satisfaction with different areas of life and their personal narrative, they were able to identify topics over time. A few (n=3) either never shared their concerns or stated they did not have any major life challenges.</p></sec></sec><sec><title>Secondary outcomes</title><p>Secondary outcomes included patient-reported measures of adherence, depression, HRQoL, and self-efficacy; furthermore, the clinical parameters (FEV<sub>1</sub>, BMI, or HbA1C) were assessed. The means and SDs of all secondary outcomes for the coaching group and the control group over the four time points are presented in two tables; <xref ref-type="table" rid="t2-ppa-11-1613">Table 2</xref> shows outcomes of HRQoL and <xref ref-type="table" rid="t3-ppa-11-1613">Table 3</xref> shows all other secondary outcomes.</p><sec><title>Adherence</title><p>Adherence was assessed using the MMAS-8 for dornase alfa, pancreatic enzymes, vitamin supplements (ADEK), inhaled antibiotic therapy, and PEP therapy. The scores on the MMAS-8 indicated that many participants (50%) were poorly adherent to pancreatic enzymes and inhaled antibiotics. However, even worse adherence was reported for PEP treatments and dornase alpha (74% not adhering) (<xref ref-type="table" rid="t4-ppa-11-1613">Table 4</xref>). Repeated measures ANOVA showed no significant result for any of the adherence outcomes; a medium effect size was found for dornase alpha over time (partial &#x003b7;<sup>2</sup>=0.137) and for PEP over time (partial &#x003b7;<sup>2</sup>=0.186) (<xref ref-type="table" rid="t5-ppa-11-1613">Table 5</xref>).</p></sec><sec><title>Depression</title><p>More than one-quarter of patients endorsed elevated symptoms of depression (26.2%) (<xref ref-type="table" rid="t4-ppa-11-1613">Table 4</xref>). There were no differences between the groups over time (<xref ref-type="table" rid="t5-ppa-11-1613">Table 5</xref>).</p></sec><sec><title>HRQoL</title><p>At baseline, CFQ-R scores were the lowest (worst) in both groups for Vitality and Treatment Burden and were highest (best) for Eating Disturbances, Weight Problems, and Role Functioning (<xref ref-type="table" rid="t2-ppa-11-1613">Table 2</xref>). There was no significant difference in any of the CFR-Q outcomes; however, an improvement in the CFQ-R Vitality in the control group gave a large effect size (partial &#x003b7;<sup>2</sup>=0.303) (<xref ref-type="table" rid="t5-ppa-11-1613">Table 5</xref>).</p></sec><sec><title>Self-efficacy</title><p>The mean self-efficacy score was 33.5 (SD 5.2) of a total score of 40. There were no differences between the groups over time (<xref ref-type="table" rid="t5-ppa-11-1613">Table 5</xref>).</p><p>No significant improvements in the PRO measures were observed in the coaching group. In addition, no significant improvements were detected in patients&#x02019; clinical parameters (FEV<sub>1</sub>, BMI, or HbA1C) (<xref ref-type="table" rid="t5-ppa-11-1613">Table 5</xref>). Neither within nor between group differences emerged in these outcome measures.</p></sec></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we evaluated the feasibility of a life coaching intervention for young adults with CF. Using a randomized controlled design, we found that 50% of participants allocated to the intervention group attended the maximum offered coaching sessions, and both face-to-face and telephone coaching were rated as convenient for participants. This study successfully recruited the desired number of consenting participants, which was set a priori (n=40). This represented 47% of our clinic sample of eligible young adults with CF. A systematic review of lifestyle interventions reported recruitment rates ranging from 7% to 28%;<xref rid="b32-ppa-11-1613" ref-type="bibr">32</xref> thus, recruitment of our target sample, which represented half of our adult clinic population, indicated significant interest in and willingness to participate in a coaching intervention.</p><p>Comparing our baseline data with a recent cross-sectional study suggested that our study population was representative of the larger Danish CF adult population in relation to age, disease severity, and educational level.<xref rid="b7-ppa-11-1613" ref-type="bibr">7</xref> One key observation was that our participants were primarily female, representing 71% of our sample. It is possible that a coaching intervention is more appealing to women than men; furthermore, given that the coach was also female, this might also have influenced the gender distribution. Baseline self-efficacy scores (mean (SD) 33.5 (5.2)) were higher than the scores among a group of German high school students (mean (SD) 29.6 (4.0)) (n=3,494).<xref rid="b33-ppa-11-1613" ref-type="bibr">33</xref> Self-efficacy is a measurement of an individual&#x02019;s belief in his or her ability to master a given task; thus, the high self-efficacy score could indicate that this group of participants already had good problem solving skills, when they entered the study.</p><p>Rates of attrition were 39% in the coaching group. Attrition rates as high as 18%&#x02013;26% are not unusual in studies of counseling interventions.<xref rid="b34-ppa-11-1613" ref-type="bibr">34</xref>,<xref rid="b35-ppa-11-1613" ref-type="bibr">35</xref> Dropout rates in previous studies have been associated with symptoms of depression, e-therapy (mental health services over the Internet), outpatient settings, and interventions that include a large number of sessions.<xref rid="b35-ppa-11-1613" ref-type="bibr">35</xref> High dropout rates have also been found in studies targeting behavior change using personal goal setting and identification of barriers.<xref rid="b34-ppa-11-1613" ref-type="bibr">34</xref> Many of the challenges associated with high dropout rates also occurred in our intervention. Thus, when designing coaching and other counseling interventions, high rates of attrition should be expected and studies should be powered to assess efficacy taking this dropout rate into account. Strategies that minimize attrition (eg, excluding those that endorse severe depression; offering fewer sessions) should be considered.</p><p>We used life coaching as a method for supporting young adults with CF to improve their HRQoL and self-efficacy and to assist them in overcoming barriers to good CF care. All coaching sessions were carried out by a single certified coach, which ensured consistency across participants and sessions. The intervention followed a general model for life coaching;<xref rid="b19-ppa-11-1613" ref-type="bibr">19</xref>,<xref rid="b20-ppa-11-1613" ref-type="bibr">20</xref> however, since coaching sessions were individualized, the approach was tailored to the specific needs of each participant.</p><p>We found that both face-to-face and telephone coaching appealed to participants. Participants preferred face-to-face coaching, but the opportunity to have telephone coaching was useful for those who lived far away or wanted to save time. Telephone coaching was also used to evaluate progress in completing action plans. Face-to-face versus telephone coaching has been evaluated in a few studies with ambiguous results: one study found both methods to be effective,<xref rid="b36-ppa-11-1613" ref-type="bibr">36</xref> but another found that face-to-face sessions were superior to telephone coaching.<xref rid="b37-ppa-11-1613" ref-type="bibr">37</xref> Our study did not compare the effectiveness of these two methods. Thus, we cannot recommend one method over another. We did, however, find that patients appreciated having both options available.</p><p>Participants discussed a variety of topics (eg, work/study&#x02013;life balance, treatment adherence, stress reduction, time management, establishing priorities, and improvement of eating or exercise habits). Similar themes have been documented in several studies, indicating that issues related to time management, treatment burden, and adherence are critical challenges for adults with CF.<xref rid="b8-ppa-11-1613" ref-type="bibr">8</xref>&#x02013;<xref rid="b10-ppa-11-1613" ref-type="bibr">10</xref> This also converged with our data on self-reported adherence. Poor adherence was reported by 50%&#x02013;76% of study participants and this topic was frequently addressed in the coaching sessions. We did not find an association between our intervention and rates of adherence, but the study was not powered to evaluate the efficacy of the intervention.</p><p>Stress reduction was also an important topic and this often involved establishing priorities, achieving a better work&#x02013;life balance, and managing time more effectively. A recent study among young adults with CF found that 52% of their study population felt that CF had a negative impact on education, employment, and other life situations, and the authors state that there is a need for additional support in these issues.<xref rid="b38-ppa-11-1613" ref-type="bibr">38</xref> The individual&#x02019;s response to stress can increase vulnerability to depression especially if persistent stress is not resolved through emotion or problem-solved coping or adaption.<xref rid="b39-ppa-11-1613" ref-type="bibr">39</xref> It would have been an advantage for our study if we had also included measuring tools to evaluate perceived stress and coping strategies.</p><p>The interval between coaching sessions and total length of the coaching program was prolonged due to frequent cancellations. There are no clear recommendations on how frequently coaching sessions should be scheduled, but one of the basic principles of coaching is that the coachees commit themselves to an action plan, with coaching sessions facilitating accountability for these plans.<xref rid="b19-ppa-11-1613" ref-type="bibr">19</xref> The risk of relapse during these stages of change may increase if the gap between coaching sessions is too wide.</p><sec><title>Limitations</title><p>Although this study is the first to explore the feasibility of a coaching intervention for young adults with CF, it had limitations. First, participants were not initially screened for their need or interest in a coaching intervention. This may have influenced their level of commitment to the intervention, especially for those who did not perceive a need for it. This may have also influenced both cancellations of appointments and dropout rates. Future studies should evaluate interest and level of motivation for participating in a life coaching session. Second, even though this was a feasibility study, which by its nature lacked power to detect any differences, the high dropout rates for the intervention group could have a negative impact of the random assignment; especially concerning are the low response rates for the questionnaires among participants who dropped out. Third, this intervention may not be appropriate for those with severe depressive symptoms. Future studies should consider screening out those who express this degree of depressive symptomatology. It is likely that they need a different type of intervention, delivered in a more intensive way. Fourth, to learn more about the individual life stressors and the strategies used to overcome barriers to manage stress in a life with CF, future studies should consider including instruments to measure perceived stress and coping strategies.</p></sec></sec><sec><title>Conclusion</title><p>Young adults with CF were willing to participate in a life coaching intervention, and almost half of the participants attended the maximum number of offered coaching sessions. The issues participants chose to work on were related to study/work&#x02013;life balance, barriers to treatment adherence, and stress. Participants preferred face-to-face coaching, but they also utilized telephone-based counseling when needed. The relatively high dropout rate early in the intervention was a concern. In future studies, participants should be screened for their interest in this type of intervention and those with severely elevated symptoms of depression should be excluded. A study using coaching to reduce stress symptoms among patients with CF should be considered.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the participants for their contribution to the study. This was an investigator initiated study. The primary investigator (KBK) is grateful to have received an unconditional grant from Gilead Sciences Inc. and from the Finsen Center, Rigshospitalet. The MMAS (8-item) content, names and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH,14725 NE 20th St Bellevue, WA 98007, USA; <email>dmorisky@gmail.com</email>.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ppa-11-1613"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spoonhower</surname><given-names>KA</given-names></name><name><surname>Davis</surname><given-names>PB</given-names></name></person-group><article-title>Epidemiology of cystic fibrosis</article-title><source>Clin Chest Med</source><year>2016</year><volume>37</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26857763</pub-id></element-citation></ref><ref id="b2-ppa-11-1613"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerem</surname><given-names>E</given-names></name><name><surname>Viviani</surname><given-names>L</given-names></name><name><surname>Zolin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Factors associated with FEV<sub>1</sub> decline in cystic fibrosis: analysis of the ECFS patient registry</article-title><source>Eur Respir J</source><year>2014</year><volume>43</volume><issue>1</issue><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="pmid">23598952</pub-id></element-citation></ref><ref id="b3-ppa-11-1613"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKenzie</surname><given-names>T</given-names></name><name><surname>Gifford</surname><given-names>AH</given-names></name><name><surname>Sabadosa</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry</article-title><source>Ann Intern Med</source><year>2014</year><volume>161</volume><issue>4</issue><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">25133359</pub-id></element-citation></ref><ref id="b4-ppa-11-1613"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Sullivan</surname><given-names>BP</given-names></name><name><surname>Freedman</surname><given-names>SD</given-names></name></person-group><article-title>Cystic fibrosis</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9678</issue><fpage>1891</fpage><lpage>1904</lpage><pub-id pub-id-type="pmid">19403164</pub-id></element-citation></ref><ref id="b5-ppa-11-1613"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quittner</surname><given-names>AL</given-names></name><name><surname>Abbott</surname><given-names>J</given-names></name><name><surname>Georgiopoulos</surname><given-names>AM</given-names></name><etal/></person-group><article-title>International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety</article-title><source>Thorax</source><year>2016</year><volume>71</volume><issue>1</issue><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">26452630</pub-id></element-citation></ref><ref id="b6-ppa-11-1613"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quittner</surname><given-names>AL</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Marynchenko</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pulmonary medication adherence and health-care use in cystic fibrosis</article-title><source>Chest</source><year>2014</year><volume>146</volume><issue>1</issue><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">24480974</pub-id></element-citation></ref><ref id="b7-ppa-11-1613"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>KB</given-names></name><name><surname>Pressler</surname><given-names>T</given-names></name><name><surname>Mortensen</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis</article-title><source>Springerplus</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>1216</fpage><pub-id pub-id-type="pmid">27516954</pub-id></element-citation></ref><ref id="b8-ppa-11-1613"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawicki</surname><given-names>GS</given-names></name><name><surname>Heller</surname><given-names>KS</given-names></name><name><surname>Demars</surname><given-names>N</given-names></name><name><surname>Robinson</surname><given-names>WM</given-names></name></person-group><article-title>Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives</article-title><source>Pediatr Pulmonol</source><year>2015</year><volume>50</volume><issue>2</issue><fpage>127</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">24616259</pub-id></element-citation></ref><ref id="b9-ppa-11-1613"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>M</given-names></name><name><surname>Rand-Giovannetti</surname><given-names>D</given-names></name><name><surname>Eakin</surname><given-names>MN</given-names></name><name><surname>Borrelli</surname><given-names>B</given-names></name><name><surname>Zettler</surname><given-names>M</given-names></name><name><surname>Riekert</surname><given-names>KA</given-names></name></person-group><article-title>Perceptions of barriers and facilitators: self-management decisions by older adolescents and adults with CF</article-title><source>J Cyst Fibros</source><year>2010</year><volume>9</volume><issue>6</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">20846910</pub-id></element-citation></ref><ref id="b10-ppa-11-1613"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bregnballe</surname><given-names>V</given-names></name><name><surname>Schi&#x000f8;tz</surname><given-names>PO</given-names></name><name><surname>Boisen</surname><given-names>KA</given-names></name><name><surname>Pressler</surname><given-names>T</given-names></name><name><surname>Thastum</surname><given-names>M</given-names></name></person-group><article-title>Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents</article-title><source>Patient Prefer Adherence</source><year>2011</year><volume>5</volume><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">22114464</pub-id></element-citation></ref><ref id="b11-ppa-11-1613"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogayzel</surname><given-names>PJ</given-names></name><name><surname>Naureckas</surname><given-names>ET</given-names></name><name><surname>Robinson</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health</article-title><source>Am J Respir Crit Care Med</source><year>2013</year><volume>187</volume><issue>7</issue><fpage>680</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">23540878</pub-id></element-citation></ref><ref id="b12-ppa-11-1613"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwlaat</surname><given-names>R</given-names></name><name><surname>Wilczynski</surname><given-names>N</given-names></name><name><surname>Navarro</surname><given-names>T</given-names></name><etal/></person-group><article-title>Interventions for enhancing medication adherence</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>11</volume><issue>11</issue><fpage>CD000011</fpage></element-citation></ref><ref id="b13-ppa-11-1613"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savage</surname><given-names>E</given-names></name><name><surname>Beirne</surname><given-names>PV</given-names></name><name><surname>Ni Chroinin</surname><given-names>M</given-names></name><name><surname>Duff</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>T</given-names></name><name><surname>Farrell</surname><given-names>D</given-names></name></person-group><article-title>Self-management education for cystic fibrosis</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><volume>7</volume><fpage>CD007641</fpage></element-citation></ref><ref id="b14-ppa-11-1613"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldbeck</surname><given-names>L</given-names></name><name><surname>Fidika</surname><given-names>A</given-names></name><name><surname>Herle</surname><given-names>M</given-names></name><name><surname>Quittner</surname><given-names>AL</given-names></name></person-group><article-title>Psychological interventions for individuals with cystic fibrosis and their families</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>6</volume><fpage>CD003148</fpage></element-citation></ref><ref id="b15-ppa-11-1613"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Rollnick</surname><given-names>S</given-names></name></person-group><source>Motivational Interviewing: Helping People Change</source><edition>3rd ed</edition><publisher-loc>New York</publisher-loc><publisher-name>Guilford Press</publisher-name><year>2013</year></element-citation></ref><ref id="b16-ppa-11-1613"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundahl</surname><given-names>B</given-names></name><name><surname>Moleni</surname><given-names>T</given-names></name><name><surname>Burke</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Motivational interviewing in medical care settings: a systematic review and meta-analysis of randomized controlled trials</article-title><source>Patient Educ Couns</source><year>2013</year><volume>93</volume><issue>2</issue><fpage>157</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">24001658</pub-id></element-citation></ref><ref id="b17-ppa-11-1613"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>LA</given-names></name><name><surname>Wolever</surname><given-names>RQ</given-names></name></person-group><article-title>Integrative health coaching and motivational interviewing: synergistic approaches to behavior change in healthcare</article-title><source>Glob Adv Health Med</source><year>2013</year><volume>2</volume><issue>4</issue><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">24416683</pub-id></element-citation></ref><ref id="b18-ppa-11-1613"><label>18</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>ICF</collab></person-group><source>ACTP Accreditation &#x02013; Program Accreditation</source><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://coachfederation.org/program/landing.cfm?ItemNumber=2151">https://coachfederation.org/program/landing.cfm?ItemNumber=2151</ext-link></comment><date-in-citation>Accessed August 31, 2017</date-in-citation></element-citation></ref><ref id="b19-ppa-11-1613"><label>19</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Whitworth</surname><given-names>L</given-names></name><name><surname>Kimsey-House</surname><given-names>H</given-names></name><name><surname>Kimsey-House</surname><given-names>K</given-names></name><name><surname>Sandahl</surname><given-names>P</given-names></name></person-group><source>Co-active Coaching: New Skills for Coaching People Toward Success in Work and Life</source><publisher-loc>Palo Alto, CA, USA</publisher-loc><publisher-name>Davies-Black Publishing</publisher-name><year>2007</year></element-citation></ref><ref id="b20-ppa-11-1613"><label>20</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Manning</surname><given-names>S</given-names></name></person-group><source>Coaching</source><edition>2nd ed</edition><publisher-loc>Oslo, Norway</publisher-loc><publisher-name>Aschehoug</publisher-name><year>2007</year></element-citation></ref><ref id="b21-ppa-11-1613"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwellnus</surname><given-names>H</given-names></name><name><surname>King</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>L</given-names></name></person-group><article-title>Client-centred coaching in the paediatric health professions: a critical scoping review</article-title><source>Disabil Rehabil</source><year>2015</year><volume>37</volume><issue>15</issue><fpage>1305</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">25289943</pub-id></element-citation></ref><ref id="b22-ppa-11-1613"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covey</surname><given-names>SR</given-names></name></person-group><article-title>The seven habits of highly effective people</article-title><source>Natl Med Leg J</source><year>1991</year><volume>2</volume><issue>2</issue><fpage>8</fpage></element-citation></ref><ref id="b23-ppa-11-1613"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Langvarig stress</collab></person-group><article-title>Aktuel viden og forslag til stress-forebyggelse &#x02013; R&#x000e5;dgivning til almen praksis. [Programme for managing long-term stress]. Center for Forebyggelse</article-title><source>Sundhedsstyrelsen</source><year>2007</year><fpage>25</fpage><comment>Danish</comment></element-citation></ref><ref id="b24-ppa-11-1613"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>DJ</given-names></name><name><surname>Kreuter</surname><given-names>M</given-names></name><name><surname>Spring</surname><given-names>B</given-names></name><etal/></person-group><article-title>How we design feasibility studies</article-title><source>Am J Prev Med</source><year>2009</year><volume>36</volume><issue>5</issue><fpage>452</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">19362699</pub-id></element-citation></ref><ref id="b25-ppa-11-1613"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Ang</surname><given-names>A</given-names></name><name><surname>Krousel-Wood</surname><given-names>M</given-names></name><name><surname>Ward</surname><given-names>HJ</given-names></name></person-group><article-title>Predictive validity of a medication adherence measure in an outpatient setting</article-title><source>J Clin Hypertens</source><year>2008</year><volume>10</volume><issue>5</issue><fpage>348</fpage><lpage>354</lpage></element-citation></ref><ref id="b26-ppa-11-1613"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krousel-Wood</surname><given-names>M</given-names></name><name><surname>Islam</surname><given-names>T</given-names></name><name><surname>Webber</surname><given-names>LS</given-names></name><name><surname>Re</surname><given-names>R</given-names></name><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Muntner</surname><given-names>P</given-names></name></person-group><article-title>New medication adherence scale versus pharmacy fill rates in hypertensive seniors</article-title><source>Am J Manag Care</source><year>2009</year><volume>15</volume><issue>1</issue><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">19146365</pub-id></element-citation></ref><ref id="b27-ppa-11-1613"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morisky</surname><given-names>DE</given-names></name><name><surname>Dimatteo</surname><given-names>MR</given-names></name></person-group><article-title>Improving the measurement of self-reported medication nonadherence: response to authors</article-title><source>J Clin Epidemiol</source><year>2011</year><volume>64</volume><issue>3</issue><fpage>255</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">21144706</pub-id></element-citation></ref><ref id="b28-ppa-11-1613"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bech</surname><given-names>P</given-names></name><name><surname>Timmerby</surname><given-names>N</given-names></name><name><surname>Martiny</surname><given-names>K</given-names></name><name><surname>Lunde</surname><given-names>M</given-names></name><name><surname>Soendergaard</surname><given-names>S</given-names></name></person-group><article-title>Psychometric evaluation of the Major Depression Inventory (MDI) as depression severity scale using the LEAD (Longitudinal Expert Assessment of All Data) as index of validity</article-title><source>BMC Psychiatry</source><year>2015</year><volume>15</volume><fpage>190</fpage><pub-id pub-id-type="pmid">26242577</pub-id></element-citation></ref><ref id="b29-ppa-11-1613"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radloff</surname><given-names>LS</given-names></name></person-group><article-title>The use of the Center for Epidemiologic Studies Depression Scale in adolescents and young adults</article-title><source>J Youth Adolesc</source><year>1991</year><volume>20</volume><issue>2</issue><fpage>149</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">24265004</pub-id></element-citation></ref><ref id="b30-ppa-11-1613"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quittner</surname><given-names>AL</given-names></name><name><surname>Sawicki</surname><given-names>GS</given-names></name><name><surname>McMullen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Erratum to: psychometric evaluation of the cystic fibrosis questionnaire revised in a national, US sample</article-title><source>Qual Life Res</source><year>2012</year><volume>21</volume><issue>7</issue><fpage>1279</fpage><lpage>1290</lpage><pub-id pub-id-type="pmid">22240933</pub-id></element-citation></ref><ref id="b31-ppa-11-1613"><label>31</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwarzer</surname><given-names>R</given-names></name><name><surname>Jerusalem</surname><given-names>M</given-names></name></person-group><article-title>General self-efficacy scale</article-title><person-group person-group-type="editor"><name><surname>Weinman</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>M</given-names></name></person-group><source>Measures in Health Psychology: A User&#x02019;s Portfolio Causal and Control Beliefs</source><publisher-loc>Windsor, UK</publisher-loc><publisher-name>NFER-NELSON</publisher-name><year>1995</year><fpage>35</fpage><lpage>37</lpage></element-citation></ref><ref id="b32-ppa-11-1613"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilinsky</surname><given-names>AS</given-names></name><name><surname>Kirk</surname><given-names>AF</given-names></name><name><surname>Hughes</surname><given-names>AR</given-names></name><name><surname>Lindsay</surname><given-names>RS</given-names></name></person-group><article-title>Lifestyle interventions for type 2 diabetes prevention in women with prior gestational diabetes: a systematic review and meta-analysis of behavioural, anthropometric and metabolic outcomes</article-title><source>Prev Med Reports</source><year>2015</year><volume>2</volume><fpage>448</fpage><lpage>461</lpage></element-citation></ref><ref id="b33-ppa-11-1613"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luszczynska</surname><given-names>A</given-names></name><name><surname>Guti&#x000e9;rrez-Do&#x000f1;a</surname><given-names>B</given-names></name><name><surname>Schwarzer</surname><given-names>R</given-names></name></person-group><article-title>General self-efficacy in various domains of human functioning: evidence from five countries</article-title><source>Int J Psychol</source><year>2005</year><volume>40</volume><issue>2</issue><fpage>80</fpage><lpage>89</lpage></element-citation></ref><ref id="b34-ppa-11-1613"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crutzen</surname><given-names>R</given-names></name><name><surname>Viechtbauer</surname><given-names>W</given-names></name><name><surname>Spigt</surname><given-names>M</given-names></name><name><surname>Kotz</surname><given-names>D</given-names></name></person-group><article-title>Differential attrition in health behaviour change trials: a systematic review and meta-analysis</article-title><source>Psychol Health</source><year>2015</year><volume>30</volume><issue>1</issue><fpage>122</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">25109224</pub-id></element-citation></ref><ref id="b35-ppa-11-1613"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Salem</surname><given-names>D</given-names></name><name><surname>Swift</surname><given-names>JK</given-names></name><name><surname>Ramtahal</surname><given-names>N</given-names></name></person-group><article-title>Meta-analysis of dropout from cognitive behavioral therapy: magnitude, timing, and moderators</article-title><source>J Consult Clin Psychol</source><year>2015</year><volume>83</volume><issue>6</issue><fpage>1108</fpage><lpage>1122</lpage><pub-id pub-id-type="pmid">26302248</pub-id></element-citation></ref><ref id="b36-ppa-11-1613"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opdenacker</surname><given-names>J</given-names></name><name><surname>Boen</surname><given-names>F</given-names></name></person-group><article-title>Effectiveness of face-to-face versus telephone support in increasing physical activity and mental health among university employees</article-title><source>J Phys Act Health</source><year>2008</year><volume>5</volume><fpage>830</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">19164818</pub-id></element-citation></ref><ref id="b37-ppa-11-1613"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Wilber</surname><given-names>KH</given-names></name><name><surname>Simmons</surname><given-names>WJ</given-names></name></person-group><article-title>Motivating high-risk older adults to exercise: does coaching matter?</article-title><source>Home Health Care Serv Q</source><year>2011</year><volume>30</volume><issue>2</issue><fpage>84</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">21590567</pub-id></element-citation></ref><ref id="b38-ppa-11-1613"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askew</surname><given-names>K</given-names></name><name><surname>Bamford</surname><given-names>J</given-names></name><name><surname>Hudson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Current characteristics, challenges and coping strategies of young people with cystic fibrosis as they transition to adulthood</article-title><source>Clin Med</source><year>2017</year><volume>17</volume><issue>2</issue><fpage>121</fpage><lpage>125</lpage></element-citation></ref><ref id="b39-ppa-11-1613"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>MC</given-names></name><name><surname>Kouros</surname><given-names>CD</given-names></name><name><surname>Fox</surname><given-names>KR</given-names></name><name><surname>Rao</surname><given-names>U</given-names></name><name><surname>Garber</surname><given-names>J</given-names></name></person-group><article-title>Interactive models of depression vulnerability: the role of childhood trauma, dysfunctional attitudes, and coping</article-title><source>Br J Clin Psychol</source><year>2014</year><volume>53</volume><fpage>245</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">24372468</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ppa-11-1613" position="float"><label>Figure 1</label><caption><p>Participant flow chart.</p></caption><graphic xlink:href="ppa-11-1613Fig1"/></fig><table-wrap id="t1-ppa-11-1613" position="float"><label>Table 1</label><caption><p>Baseline demographics and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Total</th><th valign="top" align="left" rowspan="1" colspan="1">Intervention group</th><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Number</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, mean (range)</td><td valign="top" align="left" rowspan="1" colspan="1">23.7 (18&#x02013;30)</td><td valign="top" align="left" rowspan="1" colspan="1">23.6 (18&#x02013;30)</td><td valign="top" align="left" rowspan="1" colspan="1">23.7 (18&#x02013;29)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Females, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (71)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (67)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (75)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">22.1 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">21.7 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">22.5 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> % predicted, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">73.4 (23)</td><td valign="top" align="left" rowspan="1" colspan="1">71.3 (24.7)</td><td valign="top" align="left" rowspan="1" colspan="1">75.5 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (&#x02264;40%), n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (13)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (17)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (10)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (41%&#x02013;70%), n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (37)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (39)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (35)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub> (&#x0003e;71%), n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (50)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (44)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (55)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HbA1C%, mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">6.15 (1.50)</td><td valign="top" align="left" rowspan="1" colspan="1">6.42 (1.69)</td><td valign="top" align="left" rowspan="1" colspan="1">5.86 (1.23)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CFTR mutation classes 1 or 2</td><td valign="top" align="left" rowspan="1" colspan="1">36 (95)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (100)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (90)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chronic pulmonary infection,<xref ref-type="table-fn" rid="tfn1-ppa-11-1613">a</xref> n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (55)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (56)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (55)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CFRD, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (44)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Single,<xref ref-type="table-fn" rid="tfn2-ppa-11-1613">b</xref> n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (58)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (56)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (45)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lower education, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (29)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (30)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">High school, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (28)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (35)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">College/university, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (39)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (45)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (35)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Employed or studying, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (87)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (83)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (90)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Incapacitated to work/study, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (11)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (5)</td><td valign="top" align="left" rowspan="1" colspan="1">NS</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ppa-11-1613"><label>a</label><p>Pseudomonas aeruginosa, Achromobacter xylosoxidans, and Burkholderia species.</p></fn><fn id="tfn2-ppa-11-1613"><label>b</label><p>Single status is self-reported and defined as not having a romantic partner.</p></fn><fn id="tfn3-ppa-11-1613"><p><bold>Abbreviations:</bold> FEV<sub>1</sub>, forced expiratory volume in 1 second; HbA1C, glycated hemoglobin; CFTR, cystic fibrosis transmembrane regulator protein; CFRD, cystic fibrosis-related diabetes; NS, nonsignificant; SD, standard deviation; BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ppa-11-1613" position="float"><label>Table 2</label><caption><p>Means and standard deviations of health-related quality of life scores from the CFQ-R at baseline, midway, post-intervention, and follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Measured outcome</th><th rowspan="2" valign="top" align="left" colspan="1">Treatment</th><th colspan="2" valign="top" align="left" rowspan="1">Baseline
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Midway<break/>(5 months)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Post-intervention<break/>(11 months)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Follow-up (1 year<break/>post-intervention)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">Physical Functioning</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">75 (31.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">74.4 (35.1)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">81.9 (23.1)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">68.2 (36.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">80.2 (19.7)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">76 (26)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">80.3 (21)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">78.5 (30.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Role Limitations</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">82.5 (15.8)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">80.6 (16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">78.1 (19.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">81.1 (13.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">77.9 (20.3)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">73.4 (25.3)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">83.8 (16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">87.9 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Vitality</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">46.8 (21.8)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">51.8 (21)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">49.1 (16.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">46.5 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">48.5 (18.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">50.8 (16.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">63.9 (18.5)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">57.2 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Emotional Functioning</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">67.7 (19.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">69.5 (20.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">68.1 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">67.8 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">71 (21.2)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">72.5 (17.1)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">76.9 (11.3)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">76.7 (19.2)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Social Functioning</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">67.9 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">72.2 (20.9)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">67.9 (28.6)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">67.1 (22.2)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">70.7 (18.2)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">70.7 (16.8)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">75.9 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">70.8 (24.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Body Image</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">73.5 (25.3)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">75.4 (18.6)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">72.8 (26.1)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">69.4 (25.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">76.1 (25.8)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">84.3 (20.1)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">79.6 (21)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">86.1 (15.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Eating Disturbance</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">89.5 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">88.9 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">90.1 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">93.5 (11.1)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">89.4 (22.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">88.2 (21.7)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">90.4 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">86.1 (19.0)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Treatment Burden</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">52.5 (20.8)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">52.4 (24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">51.9 (18.4)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">51.9 (16.6)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">47.9 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">52.3 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">56.8 (22.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">57.4 (25.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Health Perception</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">58.6 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">57.9 (29)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">51.9 (26.1)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">48.1 (26.1)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">58.3 (24.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">56.9 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">60.5 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">58.3 (29.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Weight Problems</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">77.8 (37.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">88.1 (28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">77.8 (33.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">80.6 (26.4)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">83.3 (36.7)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">80.4 (35.5)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">83.3 (30.8)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">80.6 (38.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Respiratory Symptoms</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">65.6 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">61.5 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">60.5 (16.5)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">60.2 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">67.2 (25)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">73.3 (21.6)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">70.1 (22.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">70.8 (20.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Digestive Symptoms</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">74.1 (25.2)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">65.9 (20.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">67.9 (23.9)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">61.1 (23.5)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">71.1 (27.1)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">81.3 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">75.7 (18.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">73.7 (25.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-ppa-11-1613"><p><bold>Abbreviations:</bold> SD, standard deviation; CFQ-R, Cystic Fibrosis Questionnaire revised version.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ppa-11-1613" position="float"><label>Table 3</label><caption><p>Means and standard deviations of secondary outcomes at baseline, midway, post-intervention, and follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Measured outcome</th><th rowspan="2" valign="top" align="left" colspan="1">Treatment</th><th colspan="2" valign="top" align="left" rowspan="1">Baseline
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Midway<break/>(5 months)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Post-intervention<break/>(11 months)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Follow-up (1 year<break/>post-intervention)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th><th valign="top" align="left" rowspan="1" colspan="1">Mean (SD)</th><th valign="top" align="left" rowspan="1" colspan="1">n</th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">Dornase alfa<xref ref-type="table-fn" rid="tfn5-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">4.25 (2.43)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">4.45 (2.44)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">4.67 (2.37)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">4.70 (1.87)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">3.86 (2.73)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">3.72 (2.33)</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">3.53 (2.67)</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">2.98 (1.77)</td><td valign="top" align="left" rowspan="1" colspan="1">10</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Pancreatic enzymes<xref ref-type="table-fn" rid="tfn5-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">5.11 (2.19)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">4.88 (1.95)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td><td valign="top" align="left" rowspan="1" colspan="1">5.53 (1.99)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">5.23 (2.15)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">6.08 (1.56)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">5.88 (1.66)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">6.32 (1.49)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">5.39 (2.12)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Vitamins supplement<xref ref-type="table-fn" rid="tfn5-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">5.14 (2.56)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">5.13 (2.19)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">5.94 (2.06)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">5.04 (2.30)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">4.93 (2.56)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">5.24 (2.70)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">5.69 (2.51)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">5.69 (2.51)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Inhaled antibiotics<xref ref-type="table-fn" rid="tfn5-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">4.50 (2.45)</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">4.52 (2.45)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">4.97 (2.47)</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">4.40 (2.46)</td><td valign="top" align="left" rowspan="1" colspan="1">8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">5.04 (2.54)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">5.03 (2.48)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">5.30 (2.31)</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">4.39 (2.32)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">PEP<xref ref-type="table-fn" rid="tfn5-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">3.81 (2.66)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">3.92 (2.84)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">4.17 (2.50)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">3.79 (2.55)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">3.62 (2.96)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">3.36 (2.55)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">3.36 (2.76)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">2.78 (1.34)</td><td valign="top" align="left" rowspan="1" colspan="1">10</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">GSE</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">32.1 (5.71)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">33.2 (5.27)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">32.9 (6.58)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">30.4 (6.44)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">32.9 (4.12)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">34.1 (4.63)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">34.9 (4.39)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">34.6 (4.32)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">MDI</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">13.6 (7.82)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">13.4 (11.2)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">11.9 (7.03)</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">12.9 (8.67)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">13.3 (10.7)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">10.9 (6.95)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">9.18 (6.00)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">10.9 (9.76)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">CES-D</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">7.89 (10.8)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">11.3 (11.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">9.71 (7.11)</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">13.3 (10.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">9.10 (9.85)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">12.5 (8.94)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">10.1 (8.51)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">12.8 (10.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">FEV<sub>1</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">71.3 (24.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">74.4 (27.9)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">69.9 (25.3)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">71.0 (23.0)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">75.5 (21.9)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">73.9 (22.5)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">73.5 (19.2)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">75.2 (23.2)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">BMI</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">21.7 (3.91)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">22.5 (4.59)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">22.0 (4.23)</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">22.2 (3.78)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">22.5 (3.93)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.7 (4.06)</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">22.1 (3.48)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">23.2 (4.53)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">HbA1c</td><td valign="top" align="left" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1">6.41 (1.69)</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">5.99 (2.31)</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">6.65 (1.76)</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">6.31 (1.53)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Control</td><td valign="top" align="left" rowspan="1" colspan="1">5.86 (1.24)</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">6.11 (1.13)</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">5.96 (1.31)</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">5.96 (0.87)</td><td valign="top" align="left" rowspan="1" colspan="1">19</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn5-ppa-11-1613"><label>a</label><p>Scores accessed by MMAS-8. The MMAS (8-item) content, names and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH,14725 NE 20th St Bellevue, WA 98007, USA; <email>dmorisky@gmail.com</email>.</p></fn><fn id="tfn6-ppa-11-1613"><p><bold>Abbreviations:</bold> SD, standard deviation; MMAS-8, Morisky Medication Adherence Scale-8; PEP, positive expiratory pressure; GSE, General Self-Efficacy; MDI, Major Depres sion Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale; FEV<sub>1</sub>, forced expiratory volume in 1 second; BMI, body mass index; HbA1c, glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ppa-11-1613" position="float"><label>Table 4</label><caption><p>Baseline and post-intervention distribution of adherence and depression scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">Baseline
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Post-intervention<break/>(11 months)
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Follow-up (1 year<break/>post-intervention)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Total<break/>group<break/>(n=38)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Coaching<break/>group<break/>(n=18)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Control<break/>group<break/>(n=20)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Coaching<break/>group<break/>(n=9)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Control<break/>group<break/>(n=18)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Coaching<break/>group<break/>(n=12)
<hr/></th><th valign="top" align="left" rowspan="1" colspan="1">Control<break/>group<break/>(n=12)
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th><th valign="top" align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Dornase alfa</td><td valign="top" align="left" rowspan="1" colspan="1">76%</td><td valign="top" align="left" rowspan="1" colspan="1">75%</td><td valign="top" align="left" rowspan="1" colspan="1">78%</td><td valign="top" align="left" rowspan="1" colspan="1">67%</td><td valign="top" align="left" rowspan="1" colspan="1">80%</td><td valign="top" align="left" rowspan="1" colspan="1">72%</td><td valign="top" align="left" rowspan="1" colspan="1">90%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low adherence<xref ref-type="table-fn" rid="tfn7-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pancreatic enzymes</td><td valign="top" align="left" rowspan="1" colspan="1">50%</td><td valign="top" align="left" rowspan="1" colspan="1">67%</td><td valign="top" align="left" rowspan="1" colspan="1">33%</td><td valign="top" align="left" rowspan="1" colspan="1">67%</td><td valign="top" align="left" rowspan="1" colspan="1">41%</td><td valign="top" align="left" rowspan="1" colspan="1">67%</td><td valign="top" align="left" rowspan="1" colspan="1">55%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low adherence<xref ref-type="table-fn" rid="tfn7-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vitamine supplements</td><td valign="top" align="left" rowspan="1" colspan="1">58%</td><td valign="top" align="left" rowspan="1" colspan="1">56%</td><td valign="top" align="left" rowspan="1" colspan="1">60%</td><td valign="top" align="left" rowspan="1" colspan="1">56%</td><td valign="top" align="left" rowspan="1" colspan="1">39%</td><td valign="top" align="left" rowspan="1" colspan="1">67%</td><td valign="top" align="left" rowspan="1" colspan="1">64%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low adherence<xref ref-type="table-fn" rid="tfn7-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Inhaled antibiotics</td><td valign="top" align="left" rowspan="1" colspan="1">56%</td><td valign="top" align="left" rowspan="1" colspan="1">64%</td><td valign="top" align="left" rowspan="1" colspan="1">50%</td><td valign="top" align="left" rowspan="1" colspan="1">63%</td><td valign="top" align="left" rowspan="1" colspan="1">53%</td><td valign="top" align="left" rowspan="1" colspan="1">64%</td><td valign="top" align="left" rowspan="1" colspan="1">64%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low adherence<xref ref-type="table-fn" rid="tfn7-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PEP</td><td valign="top" align="left" rowspan="1" colspan="1">74%</td><td valign="top" align="left" rowspan="1" colspan="1">75%</td><td valign="top" align="left" rowspan="1" colspan="1">74%</td><td valign="top" align="left" rowspan="1" colspan="1">78%</td><td valign="top" align="left" rowspan="1" colspan="1">75%</td><td valign="top" align="left" rowspan="1" colspan="1">83%</td><td valign="top" align="left" rowspan="1" colspan="1">100%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Low adherence<xref ref-type="table-fn" rid="tfn7-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MDI</td><td valign="top" align="left" rowspan="1" colspan="1">15.7%</td><td valign="top" align="left" rowspan="1" colspan="1">17%</td><td valign="top" align="left" rowspan="1" colspan="1">15%</td><td valign="top" align="left" rowspan="1" colspan="1">22%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">8.3%</td><td valign="top" align="left" rowspan="1" colspan="1">8.3%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mild depression</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MDI</td><td valign="top" align="left" rowspan="1" colspan="1">2.6%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">5%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">5.6%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">17%</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate depression</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MDI</td><td valign="top" align="left" rowspan="1" colspan="1">7.9%</td><td valign="top" align="left" rowspan="1" colspan="1">5.6%</td><td valign="top" align="left" rowspan="1" colspan="1">10%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">8.3%</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Severe depression</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CES-D depression<xref ref-type="table-fn" rid="tfn8-ppa-11-1613">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">26%</td><td valign="top" align="left" rowspan="1" colspan="1">22%</td><td valign="top" align="left" rowspan="1" colspan="1">30%</td><td valign="top" align="left" rowspan="1" colspan="1">22%</td><td valign="top" align="left" rowspan="1" colspan="1">22%</td><td valign="top" align="left" rowspan="1" colspan="1">25%</td><td valign="top" align="left" rowspan="1" colspan="1">25%</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn7-ppa-11-1613"><label>a</label><p>Low adherence: Morisky Medication Adherence Scale-8 item scores &#x0003c;6.</p></fn><fn id="tfn8-ppa-11-1613"><label>b</label><p>Depression: CES-D scores &#x0003e;16.</p></fn><fn id="tfn9-ppa-11-1613"><p><bold>Abbreviations:</bold> PEP, positive expiratory pressure; MDI, Major Depression Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-ppa-11-1613" position="float"><label>Table 5</label><caption><p>The main effects between the intervention group and the control group over time (baseline, midway, post-intervention, and follow-up) on secondary outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Measured outcomes</th><th valign="top" align="left" rowspan="1" colspan="1">Factor</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Partial &#x003b7;<sup>2</sup></th><th valign="top" align="left" rowspan="1" colspan="1">Measured outcomes</th><th valign="top" align="left" rowspan="1" colspan="1">Factor</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">Partial &#x003b7;<sup>2</sup></th></tr></thead><tbody><tr><td rowspan="2" valign="top" align="left" colspan="1">Physical Functioning<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time<xref ref-type="table-fn" rid="tfn11-ppa-11-1613">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td><td valign="top" align="left" rowspan="1" colspan="1">0.132</td><td valign="top" align="left" rowspan="1" colspan="1">Dornase alpha<xref ref-type="table-fn" rid="tfn14-ppa-11-1613">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.17</td><td valign="top" align="left" rowspan="1" colspan="1">0.137</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group<xref ref-type="table-fn" rid="tfn12-ppa-11-1613">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.73</td><td valign="top" align="left" rowspan="1" colspan="1">0.008</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td><td valign="top" align="left" rowspan="1" colspan="1">0.210</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Role Limitations<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.41</td><td valign="top" align="left" rowspan="1" colspan="1">0.058</td><td valign="top" align="left" rowspan="1" colspan="1">Pancreatic enzymes<xref ref-type="table-fn" rid="tfn14-ppa-11-1613">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.20</td><td valign="top" align="left" rowspan="1" colspan="1">0.103</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.59</td><td valign="top" align="left" rowspan="1" colspan="1">0.021</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.68</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Vitality<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.16</td><td valign="top" align="left" rowspan="1" colspan="1">0.303</td><td valign="top" align="left" rowspan="1" colspan="1">Vitamins supplement<xref ref-type="table-fn" rid="tfn14-ppa-11-1613">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.55</td><td valign="top" align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td><td valign="top" align="left" rowspan="1" colspan="1">0.064</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.44</td><td valign="top" align="left" rowspan="1" colspan="1">0.044</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Emotional Functioning<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.36</td><td valign="top" align="left" rowspan="1" colspan="1">0.063</td><td valign="top" align="left" rowspan="1" colspan="1">Inhaled antibiotics<xref ref-type="table-fn" rid="tfn14-ppa-11-1613">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.79</td><td valign="top" align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.52</td><td valign="top" align="left" rowspan="1" colspan="1">0.027</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.95</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Social Functioning<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.67</td><td valign="top" align="left" rowspan="1" colspan="1">0.138</td><td valign="top" align="left" rowspan="1" colspan="1">PEP<xref ref-type="table-fn" rid="tfn14-ppa-11-1613">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.186</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.91</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.32</td><td valign="top" align="left" rowspan="1" colspan="1">0.076</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Body Image<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.74</td><td valign="top" align="left" rowspan="1" colspan="1">0.047</td><td valign="top" align="left" rowspan="1" colspan="1">GSE</td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.31</td><td valign="top" align="left" rowspan="1" colspan="1">0.094</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.26</td><td valign="top" align="left" rowspan="1" colspan="1">0.078</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.71</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Eating Disturbance<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.43</td><td valign="top" align="left" rowspan="1" colspan="1">0.049</td><td valign="top" align="left" rowspan="1" colspan="1">MDI</td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.15</td><td valign="top" align="left" rowspan="1" colspan="1">0.112</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.61</td><td valign="top" align="left" rowspan="1" colspan="1">0.017</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.35</td><td valign="top" align="left" rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Treatment Burden<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td><td valign="top" align="left" rowspan="1" colspan="1">0.034</td><td valign="top" align="left" rowspan="1" colspan="1">CES-D</td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.15</td><td valign="top" align="left" rowspan="1" colspan="1">0.114</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.84</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.94</td><td valign="top" align="left" rowspan="1" colspan="1">0.00</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Health Perception<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.03</td><td valign="top" align="left" rowspan="1" colspan="1">0.177</td><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.40</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.36</td><td valign="top" align="left" rowspan="1" colspan="1">0.053</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.91</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Weight Problems<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.73</td><td valign="top" align="left" rowspan="1" colspan="1">0.020</td><td valign="top" align="left" rowspan="1" colspan="1">BMI</td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.73</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.91</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Respiratory Symptoms<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.18</td><td valign="top" align="left" rowspan="1" colspan="1">0.096</td><td valign="top" align="left" rowspan="1" colspan="1">HbA1C</td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.17</td><td valign="top" align="left" rowspan="1" colspan="1">0.226</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td><td valign="top" align="left" rowspan="1" colspan="1">0.197</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.56</td><td valign="top" align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td rowspan="2" valign="top" align="left" colspan="1">Digestive Symptoms<xref ref-type="table-fn" rid="tfn13-ppa-11-1613">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">Time</td><td valign="top" align="left" rowspan="1" colspan="1">0.69</td><td valign="top" align="left" rowspan="1" colspan="1">0.032</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Group</td><td valign="top" align="left" rowspan="1" colspan="1">0.68</td><td valign="top" align="left" rowspan="1" colspan="1">0.013</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn10-ppa-11-1613"><p><bold>Notes:</bold> Data were analyzed using a two-way repeated ANOVA.</p></fn><fn id="tfn11-ppa-11-1613"><label>a</label><p>Within-subject factors: repeated time measures (baseline, midway, post-intervention, and follow-up).</p></fn><fn id="tfn12-ppa-11-1613"><label>b</label><p>Between-subject factors: coaching group (n=7)/control group (n=11).</p></fn><fn id="tfn13-ppa-11-1613"><label>c</label><p>Scores assessed by CFQ-R.</p></fn><fn id="tfn14-ppa-11-1613"><label>d</label><p>Scores assessed by MMAS-8.</p></fn><fn id="tfn15-ppa-11-1613"><p><bold>Abbreviations:</bold> CFQ-R, Cystic Fibrosis Questionnaire revised version; MMAS-8, Morisky Medication Adherence Scale-8; PEP, positive expiratory pressure; GSE, General Self-Efficacy; MDI, Major Depression Inventory; CES-D, Center for Epidemiologic Studies-Depression Scale; FEV<sub>1</sub>, forced expiratory volume in 1 second; BMI, body mass index; HbA1c, glycated hemoglobin; ANOVA, analysis of variance.</p></fn></table-wrap-foot></table-wrap></floats-group></article>